To ask the Scottish Government, in light of reports that Dexamethasone is effective for the treatment of COVID-19, and that, because it is out of patent, it is inexpensive, whether will it use its Crown Use Licence powers to override any patents on other COVID-19 treatments to help ensure affordability and accessibility, including Remdesivir, which has reportedly being set a charge of $2,340 by its manufacturer for a course of treatment. The regulation of medicine...